Literature DB >> 15480811

Gaps and junctions between clinical experience and theoretical framework in the use of opioids.

Marianne Kloke.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15480811     DOI: 10.1007/s00520-004-0711-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  23 in total

1.  [Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002): opioid analgesics with the exception of morphine by mouth and the rotation].

Authors:  Sylvie Rostaing-Rigattieri; Hubert Rousselot; Ivan Krakowski; Serge Theobald; Elisabeth Collin; Nicole Vuillemin; Laurent Balp; Gérard Torloting; Bernard Fergane; Bruno Richard; Roseline Duclos; Alain Eschalier; Thierry Delorme; Christian Minello; Sophie Toussaint; Anne Richard; Marc Magnet; Giselle Chvetzoff; François Larue; Marie-Louise Navez; Olivier Collard; Marie-Pierre Bonnefoi; Monique Couturier; Nadia Santolaria; Jean-Philippe Wagner; Nicolas Fabre
Journal:  Bull Cancer       Date:  2003 Aug-Sep       Impact factor: 1.276

2.  Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life.

Authors:  S Grond; D Zech; S A Schug; J Lynch; K A Lehmann
Journal:  J Pain Symptom Manage       Date:  1991-10       Impact factor: 3.612

3.  A prospective multicenter assessment of the Edmonton staging system for cancer pain.

Authors:  E Bruera; T Schoeller; R Wenk; T MacEachern; S Marcelino; J Hanson; M Suarez-Almazor
Journal:  J Pain Symptom Manage       Date:  1995-07       Impact factor: 3.612

4.  A validation study of the WHO method for cancer pain relief.

Authors:  V Ventafridda; M Tamburini; A Caraceni; F De Conno; F Naldi
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

5.  Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.

Authors:  E Bruera; J Pereira; S Watanabe; M Belzile; N Kuehn; J Hanson
Journal:  Cancer       Date:  1996-08-15       Impact factor: 6.860

6.  An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.

Authors:  A Caraceni; R K Portenoy
Journal:  Pain       Date:  1999-09       Impact factor: 6.961

7.  The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

Authors:  Jörn Lötsch; Carsten Skarke; Sabine Grösch; Jutta Darimont; Helmut Schmidt; Gerd Geisslinger
Journal:  Pharmacogenetics       Date:  2002-01

Review 8.  Opioids and renal function.

Authors:  Sebastiano Mercadante; Edoardo Arcuri
Journal:  J Pain       Date:  2004-02       Impact factor: 5.820

9.  Addition of a second opioid may improve opioid response in cancer pain: preliminary data.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

Review 10.  A therapeutic strategy to prevent morphine dependence and tolerance by coadministration of cAMP-related reagents with morphine.

Authors:  A Itoh; Y Noda; T Mamiya; T Hasegawa; T Nabeshima
Journal:  Methods Find Exp Clin Pharmacol       Date:  1998-09
View more
  4 in total

Review 1.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

Review 2.  [Diagnosis and therapy of tumor related pain].

Authors:  M Kloke
Journal:  Urologe A       Date:  2007-01       Impact factor: 0.639

Review 3.  [Treatment of chronic pain in the internist's practice].

Authors:  W Köster
Journal:  Internist (Berl)       Date:  2005-04       Impact factor: 0.743

Review 4.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.